77 related articles for article (PubMed ID: 21807325)
1. Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial.
Bosch X; Esteve J; Sitges M; de Caralt TM; Domènech A; Ortiz JT; Monzó M; Morales-Ruiz M; Perea RJ; Rovira M
J Card Fail; 2011 Aug; 17(8):643-8. PubMed ID: 21807325
[TBL] [Abstract][Full Text] [Related]
2. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).
Bosch X; Rovira M; Sitges M; Domènech A; Ortiz-Pérez JT; de Caralt TM; Morales-Ruiz M; Perea RJ; Monzó M; Esteve J
J Am Coll Cardiol; 2013 Jun; 61(23):2355-62. PubMed ID: 23583763
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
[TBL] [Abstract][Full Text] [Related]
4. Enalapril/carvedilol for prevention of chemotherapy-induced heart failure: an end to the problem.
Golwala H
J Am Coll Cardiol; 2013 Dec; 62(25):2450-2451. PubMed ID: 24013049
[No Abstract] [Full Text] [Related]
5. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction.
Spallarossa P; Guerrini M; Arboscello E; Sicbaldi V
J Am Coll Cardiol; 2013 Dec; 62(25):2451-2452. PubMed ID: 24013048
[No Abstract] [Full Text] [Related]
6. Reply: Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies.
Bosch X; Sitges M; Rovira M; Ortiz-Pérez JT; Esteve J
J Am Coll Cardiol; 2013 Dec; 62(25):2452. PubMed ID: 24013047
[No Abstract] [Full Text] [Related]
7. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
8. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM
Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction.
Gandhi PS; Goyal RK; Jain AR; Mallya BS; Gupta VM; Shah DS; Trivedi BR; Shastri NA; Mehta CB; Jain KA; Bhavasar NS; Shah UJ
Can J Physiol Pharmacol; 2007 Feb; 85(2):193-9. PubMed ID: 17487260
[TBL] [Abstract][Full Text] [Related]
10. Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.
Guglin M; Munster P; Fink A; Krischer J
Am Heart J; 2017 Jun; 188():87-92. PubMed ID: 28577685
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
12. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection during chemotherapy: need for faster transfer of knowledge from cardiology to oncology and role for a cardio-oncologist.
Smiseth OA; Edvardsen T; Skulstad H
J Am Coll Cardiol; 2013 Jun; 61(23):2363-4. PubMed ID: 23583243
[No Abstract] [Full Text] [Related]
14. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO
Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291
[TBL] [Abstract][Full Text] [Related]
15. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
Tatli E; Kurum T
Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
[TBL] [Abstract][Full Text] [Related]
16. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.
Elitok A; Oz F; Cizgici AY; Kilic L; Ciftci R; Sen F; Bugra Z; Mercanoglu F; Oncul A; Oflaz H
Cardiol J; 2014; 21(5):509-15. PubMed ID: 24142687
[TBL] [Abstract][Full Text] [Related]
17. Rapid carvedilol up-titration in hospitalized patients with left ventricular systolic dysfunction--data from the Carvedilol in Hospital: Up-titration Limits after Acute Patients Admission registry.
Martínez-Sellés M; Datino T; Alhama M; Barrueco N; Castillo I; Fernández-Avilés F
J Cardiovasc Med (Hagerstown); 2010 May; 11(5):352-8. PubMed ID: 20154635
[TBL] [Abstract][Full Text] [Related]
18. [Beta blockers and ACE inhibitors In heart failure to be combined at the beginning!].
MMW Fortschr Med; 2002 Nov; 144(45):58. PubMed ID: 12534067
[No Abstract] [Full Text] [Related]
19. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Tsuyuki RT; Yusuf S; Rouleau JL; Maggioni AP; McKelvie RS; Wiecek EM; Wang Y; Pogue J; Teo KK; White M; Avezum A; Latini R; Held P; Lindgren E; Probstfield J
Can J Cardiol; 1997 Dec; 13(12):1166-74. PubMed ID: 9444298
[TBL] [Abstract][Full Text] [Related]
20. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
